Dual anticancer role of metformin: an old drug regulating AMPK dependent/independent pathways in metabolic,oncogenic/tumorsuppresing and immunity context |
| |
| Authors: | Maja S Misirkic Marjanovic Ljubica M Vucicevic Ana R Despotovic Marina M Stamenkovic Kristina D Janjetovic |
| |
| Institution: | 1. Department of Neurophysiology, Institute for Biological Research “Sinisa Stankovic”, National Institute of Republic of Serbia, University of Belgrade, Serbia ; 2. Department of Immunology, Institute of Microbiology and Immunology, Faculty of Medicine, University of Belgrade, Serbia |
| |
| Abstract: | Metformin has been known to treat type 2 diabetes for decades and is widely prescribed antidiabetic drug. Recently, its anticancer potential has also been discovered. Moreover, metformin has low cost thus it has attained profound research interest. Comprehensing the complexity of the molecular regulatory networks in cancer provides a mode for advancement of research in cancer development and treatment. Metformin targets many pathways that play an important role in cancer cell survival outcome. Here, we described anticancer activity of metformin on the AMPK dependent/independent mechanisms regulating metabolism, oncogene/tumor suppressor signaling pathways together with the issue of clinical studies. We also provided brief overwiev about recently described metformin’s role in cancer immunity. Insight in these complex molecular networks, will simplify application of metformin in clinical trials and contribute to improvement of anti-cancer therapy. |
| |
| Keywords: | Metformin cancer AMPK metabolism oncogenes tumor suppressors immunity |
|
|
